$77.74
+1.64 (+2.16%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CYTK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
41 interventional · 21 with posted results
Held by 20 tracked-famous managers (Point72 Asset Management, L.P., SUSQUEHANNA INTERNATIONAL GROUP, LLP, Holocene Advisors, LP, D. E. Shaw & Co., Inc., Balyasny Asset Management L.P., +15 more) · FINRA short interest 9.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 9 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).NCT06412666Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G)Randomized · Triple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Aficamten, Placebo | Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy | 65 | Jan 2030 | ≤ 1,260 d | 2026-08-18 |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMNCT04848506Incidence of adverse events observed during dosing of aficamten in patients with HCMOpen-label · Treatment | Phase 2/3 | Enrolling by invitation | Drug: Aficamten (5 - 20 mg) | Symptomatic Hypertrophic Cardiomyopathy (HCM) | 900 | Mar 2028 | ≤ 589 d | 2026-01-22 |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or strokeRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Omecamtiv Mecarbil (OM), Placebo | Heart Failure, Heart Failure With Reduced Ejection Fraction | 1,800 | Sep 2027 | ≤ 406 d | 2026-08-18 |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFNCT06793371Incidence of early drug discontinuationRandomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | 60 | Sep 2026 | ≤ 41 d | 2026-05-29 |
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)NCT06081894Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Aficamten, Placebo | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | 500 | Aug 2026 | ≤ 11 d | 2026-08-05 |
| Omecamtiv Mecarbil Post-trial Access StudyNCT04464525Number of participants administered omecamtiv mecarbil during the treatment periodOpen-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: Omecamtiv mecarbil | Chronic Heart Failure With Reduced Ejection Fraction | 0 | 2026-11-27 | in 99 d | 2021-07-30 |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMNCT05767346results2026-06-09Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 175 | 2025-02-28actual | — | 2026-06-09 |
| A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult ParticipantsNCT05877053Incidence and severity of AEsRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: CK-4021586, Placebo for CK-4021586 | Healthy Participants | 102 | 2024-11-20actual | — | 2025-05-01 |
| Study to Evaluate the Effect of Aficamten Administration on QT/QTc IntervalNCT05924815Part A: To determine the dose for Part BRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: Aficamten, Aficamten-matching Placebo, Moxifloxacin | Healthy Participants | 44 | 2023-11-14actual | — | 2023-12-19 |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMNCT05186818results2026-03-03Change From Baseline in pVO2 at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 282 | 2023-11-10actual | — | 2026-03-03 |
| A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult ParticipantsNCT05662215Incidence and severity of AEsRandomized · Triple-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: Terminated early per sponsor decision. | Drug: CK-3828136, Placebo for CK-3828136 | Healthy Participants | 57 | 2023-08-08actual | — | 2024-10-17 |
| A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT04944784results2024-12-05Effect of Reldesemtiv Versus Placebo on Functional Outcomes in Amyotrophic Lateral Sclerosis (ALS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The DMC recommended the trial be discontinued due to futility following a planned second interim analysis. | Drug: Reldesemtiv, Placebo | Amyotrophic Lateral Sclerosis | 489 | 2023-07-18actual | — | 2024-12-05 |
| A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)NCT05442775results2024-08-13Long-term Safety and TolerabilityOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The DMC recommended the trial be discontinued due to futility following a planned second interim analysis of the parent trial (CY 5031). | Drug: Reldesemtiv | Amyotrophic Lateral Sclerosis | 71 | 2023-06-07actual | — | 2024-08-13 |
| Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyNCT04219826results2026-02-24Incidence of Adverse Events (AEs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274 | Hypertrophic Cardiomyopathy (HCM) | 96 | 2023-02-28actual | — | 2026-02-24 |
| Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureNCT03759392results2023-03-07Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Omecamtiv Mecarbil, Placebo | Heart Failure With Reduced Ejection Fraction | 276 | 2021-11-08actual | — | 2023-03-07 |
| Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329results2021-07-20Time to Cardiovascular Death or First Heart Failure EventRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Omecamtiv Mecarbil, Placebo, Standard of Care | Heart Failure | 8,256 | 2020-09-14actual | — | 2021-11-05 |
| Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy AdultsNCT04175808results2021-07-20Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part BRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: SAP Version 1 ↗ | Phase 1 | Completed | Drug: Omecamtiv Mecarbil (OM), Placebo, Moxifloxacin | QT Intervals Changes, QTc Intervals Changes | 70 | 2020-03-04actual | — | 2025-03-30 |
| A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsNCT03767855Incidence of Adverse events and Safety Signals observed during single and multiple ascending doses of CK-3773274 administered orally to healthy adult subjects.Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets | Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects | 114 | 2020-01-03actual | — | 2025-01-24 |
| A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03160898results2020-09-11Change From Baseline to Week 12 in the Percent Predicted Slow Vital Capacity (SVC)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Reldesemtiv, Placebo | Amyotrophic Lateral Sclerosis | 458 | 2019-03-07actual | — | 2020-09-11 |
| A Study for Patients Who Completed VITALITY-ALS (CY 4031)NCT02936635results2021-05-12Number of Participants With Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: tirasemtiv | Amyotrophic Lateral Sclerosis (ALS) | 280 | 2018-10-26actual | — | 2021-06-15 |
| A Study of CK-2127107 in Patients With Spinal Muscular AtrophyNCT02644668results2020-08-31Change From Baseline to Week 8 in Forced Vital Capacity (FVC)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, Reldesemtiv 150 mg, Reldesemtiv 450 mg | Spinal Muscular Atrophy | 70 | 2018-05-31actual | — | 2020-08-31 |
| Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionNCT02695420results2020-01-31Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over TimeRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: 25 mg Omecamtiv Mecarbil, Placebo, 37.5 mg Omecamtiv Mecarbil, 50 mg Omecamtiv Mecarbil | Heart Failure With Reduced Ejection Fraction | 81 | 2017-04-06actual | — | 2021-07-27 |
| Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearNCT02496767results2020-06-19Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tirasemtiv, Placebo tablets | Amyotrophic Lateral Sclerosis | 744 | 2017-03-09actual | — | 2020-09-09 |
| Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese AdultsNCT02601001results2021-05-18Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Omecamtiv mecarbil, Placebo | Healthy Volunteer | 50 | 2016-01-06actual | — | 2021-07-27 |
| COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart FailureNCT01786512results2021-05-17Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2 | Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram | 544 | 2015-07-22actual | — | 2021-08-12 |
| Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)NCT01709149results2020-03-31The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind TreatmentRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CK-2017357, Riluzole · Other: Placebo tablets | Amyotrophic Lateral Sclerosis | 711 | Mar 2014actual | — | 2020-03-31 |
| Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)NCT01300013The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Omecamtiv mecarbil | Heart Failure | 614 | Apr 2013actual | — | 2021-07-27 |
| Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal InsufficiencyNCT01737866AMG 423 Pharmacokinetic ParametersNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AMG 423 | Heart Failure | 13 | Jan 2013actual | — | 2021-07-30 |
| Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia GravisNCT01268280Quantitative Myasthenia Gravis score (QMG)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Closed after complete treatment of 32 patients after 21 months' recruitment. | Drug: Placebo, 250 mg CK-2017357, 500 mg CK-2017357 | Myasthenia Gravis | 32 | Oct 2012actual | — | 2019-09-24 |
| A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01378676Number of Participants with Adverse Events as a Measure of Safety and TolerabilityRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo (Part A), CK-2017357 (Part A), CK-2017357 (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B), CK-2017357 (Part B), CK-2017357 (Part B) | Amyotrophic Lateral Sclerosis | 49 | Mar 2012actual | — | 2019-05-07 |
| Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01486849Number of participants with adverse eventsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CK-2017357, Placebo, Riluzole 50 MG | Amyotrophic Lateral Sclerosis | 27 | Mar 2012actual | — | 2019-05-03 |
| Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure PatientsNCT01077167Pharmacokinetic profile of oral formulations of Omecamtiv mecarbil following the morning dose on Days 7 and 8Open-label · Basic science | Phase 2 | Withdrawnsponsor's stated reason: Study cancelled due to sponsor's decision to redesign the study | Drug: Omecamtiv mecarbil | Heart Failure | 0 | May 2011actual | — | 2021-07-30 |
| A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic ClaudicationNCT01131013Effect of single dose of CK-2017357 on number of contractions, time and work to onset of claudication during bilateral heel raisesRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, 375 mg CK-2017357, 500 mg CK-2017357 | Intermittent Claudication, Peripheral Artery Disease | 61 | Mar 2011actual | — | 2019-05-14 |
| A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01089010ALSFRS-RRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, 250 mg CK-2017357, 500 mg CK-2017357 | Amyotrophic Lateral Sclerosis | 67 | Nov 2010actual | — | 2019-05-10 |
| A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin LymphomaNCT00343564results2016-10-04Phase 1: Determination of Maximum Tolerated Dose (MTD) First Without and Then With Administration of Prophylactic G-CSF.Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: SB-743921, SB-743921 | Non-Hodgkin's Lymphoma, Hodgkin's Disease | 68 | Jul 2010actual | — | 2020-01-13 |
| A Study of Ispinesib in Metastatic Breast CancerNCT00607841Dose Limiting Toxicity and Maximum Tolerated Dose of ispinesib administered as a 1-hr intravenous infusion on Day 1 of a 28-day cycle in female patients with Stage IIIB or IV breast cancerNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Trial stopped for administrative reasons prior to official determination of MTD. | Drug: Ispinesib, Ispinesib, Ispinesib | Breast Neoplasms | 16 | Nov 2009actual | — | 2019-05-06 |
| Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart FailureNCT00941681results2010-12-21C Max (Day 1, Dose 1)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: CK-1827452, CK-1827452, CK-1827452 | Heart Failure | 35 | Oct 2009actual | — | 2013-02-12 |
| A Study of CK-1827452 Infusion in Stable Heart FailureNCT00624442results2010-08-16Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma ConcentrationsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, Placebo, Placebo, CK-1827452, Placebo, CK-1827452, CK-1827452, CK-1827452, CK-1827452 | Heart Failure | 45 | Feb 2009actual | — | 2021-05-14 |
| PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and AnginaNCT00682565results2010-02-25Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg capsule, CK-1827452 48 mg and 11 mg iv infusion, CK-1827452 25mg capsule, Placebo iv infusion, Placebo capsule | Heart Failure, Myocardial Ischemia, Angina Pectoris | 94 | Nov 2008actual | — | 2018-08-21 |
| Phase II Study of the Effect of CK-1827452 Injection on Myocardial EfficiencyNCT00748579results2010-08-23Effect of CK-1827452 on Myocardial Efficiency, Defined as the Ratio of Ventricular Performance to Myocardial Oxygen Consumption.Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Decision to discontinue due to challenges of trial design and constraints on enrolling eligible and consenting patients. | Drug: CK-1827452, CK-1827452 | Heart Failure | 2 | Nov 2008actual | — | 2020-01-21 |
| A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy VolunteersNCT01380223Maximum Tolerated Dose (MTD) of Omecamtiv Mecarbil in Healthy VolunteersRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: placebo, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil | Heart Failure | 35 | Apr 2006actual | — | 2015-10-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19